

# Kerstin Nolle Vokinger

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5744711/kerstin-noelle-vokinger-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

27  
papers

389  
citations

11  
h-index

19  
g-index

32  
ext. papers

673  
ext. citations

11.7  
avg, IF

5.01  
L-index

#	Paper	IF	Citations
27	Approval of artificial intelligence and machine learning-based medical devices in the USA and Europe (2015-20): a comparative analysis. <i>The Lancet Digital Health</i> , <b>2021</b> , 3, e195-e203	14.4	71
26	Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis. <i>Lancet Oncology</i> , <b>2020</b> , 21, 664-670	21.7	55
25	Lifecycle Regulation of Artificial Intelligence- and Machine Learning-Based Software Devices in Medicine. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 322, 2285-2286	27.4	52
24	Digital health and the COVID-19 epidemic: an assessment framework for apps from an epidemiological and legal perspective. <i>Swiss Medical Weekly</i> , <b>2020</b> , 150, w20282	3.1	36
23	Vertebral body insufficiency fractures: detection of vertebrae at risk on standard CT images using texture analysis and machine learning. <i>European Radiology</i> , <b>2019</b> , 29, 2207-2217	8	35
22	Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study. <i>BMJ</i> , <b>2020</b> , 371, m3434	5.9	22
21	Continual learning in medical devices: FDA's action plan and beyond. <i>The Lancet Digital Health</i> , <b>2021</b> , 3, e337-e338	14.4	14
20	Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs. <i>JAMA Internal Medicine</i> , <b>2019</b> , 179, 374-380	11.5	14
19	Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe. <i>JAMA Oncology</i> , <b>2021</b> , 7, e212026	13.4	14
18	Application of orphan drug designation to cancer treatments (2008-2017): a comprehensive and comparative analysis of the USA and EU. <i>BMJ Open</i> , <b>2019</b> , 9, e028634	3	12
17	Impact of time-of-flight PET on quantification accuracy and lesion detection in simultaneous F-choline PET/MRI for prostate cancer. <i>EJNMMI Research</i> , <b>2018</b> , 8, 41	3.6	7
16	Hochpreisigkeit bei Onkologika <b>2021</b> , 79-92		6
15	Applicability of color-coded computed tomography images in lung volume reduction surgery planning. <i>Journal of Thoracic Disease</i> , <b>2019</b> , 11, 766-776	2.6	5
14	Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018. <i>Health Policy</i> , <b>2020</b> , 124, 261-267	3.2	5
13	Lost in Anonymization - A Data Anonymization Reference Classification Merging Legal and Technical Considerations. <i>Journal of Law, Medicine and Ethics</i> , <b>2020</b> , 48, 228-231	1.2	4
12	Characteristics of trials and regulatory pathways leading to US approval of innovative vs. non-innovative oncology drugs. <i>Health Policy</i> , <b>2019</b> , 123, 721-727	3.2	3
11	Regulating AI in medicine in the United States and Europe. <i>Nature Machine Intelligence</i> , <b>2021</b> , 3, 738-739	2.5	3

10	Evaluating New Rules on Transparency in Cancer Research and Drug Development. <i>JAMA Oncology</i> , <b>2019</b> , 5, 461-462	13.4	2
9	New EU regulation on health technology assessment of cancer medicines.. <i>Lancet Oncology, The</i> , <b>2022</b> , 23, e58	21.7	2
8	Value-based pricing of drugs with multiple indications or in combinations - lessons from Europe. <i>Nature Reviews Clinical Oncology</i> , <b>2021</b> ,	19.4	2
7	Therapeutic Value Assessments of Novel Medicines in the US and Europe, 2018-2019.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e226479	10.4	2
6	Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia. <i>JCO Oncology Practice</i> ,	2.3	2
5	Kosten-Nutzen-Bewertung von Arzneimitteln <b>2021</b> , 57-66		1
4	PatientsVaccess to drugs with rebates in Switzerland - Empirical analysis and policy implications for drug pricing in Europe. <i>Lancet Regional Health - Europe, The</i> , <b>2021</b> , 3, 100050		1
3	Access to Cancer Precision Medicines in Switzerland: A Comparative Analysis (USA and EU) and Health Policy Implications. <i>Public Health Genomics</i> , <b>2018</b> , 21, 238-243	1.9	1
2	Pharmacoepidemiology and the Law <b>2019</b> , 140-163		
1	Factors associated with change in the magnitude of clinical benefit of anti-cancer drugs in the post-marketing period.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 7052-7052	2.2	